The Tolerability and Effects of AZD0530 in Individuals With or Without a Family History of Alcoholism

NCT02262026 ↗

Phase 1 Completed 49 enrolled Yale University

RandomizedCrossoverSingle-blindTreatment

Summary

Functional neuroimaging of alcoholism vulnerability: glutamate, reward, impulsivity, and Pavlovian-to-instrumental transfer (PIT), part II Saracatinib

Timeline

Start: 2014-11-01
Primary completion: 2019-04-26
Completion: 2019-04-26

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	saracatinib	Small molecule	50 mg	Oral
Subject	saracatinib	Small molecule	125 mg	Oral

The Tolerability and Effects of AZD0530 in Individuals With or Without a Family History of Alcoholism

Summary

Timeline

Drugs

Indications